Formycon
Executives
View the org chart displaying its 9 main executives
Most searched biographies at Formycon
- Stefan Glombitza, Chief Executive Officer and Director
- Peter Wendeln, Vice Chairman of the Board
- Olaf Stiller, Chairman of the Board
Create your alert
to follow the executive moves at Formycon.
Pharmaceuticals
Formycon has 1,861 competitors including Pfizer (United States (USA)), Sanofi (France) and Johnson & Johnson (United States (USA)).
Popular M&A news in Pharmaceuticals
- MedMen has filed for bankruptcy protection (posted on April 28 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (posted on March 23 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (posted on March 19 2024).
Popular contacts in Pharmaceuticals
News
Press releases by Formycon
- Formycon invites to the conference call on the results of the financial year 2023 and announces participation in international investor conferences in the 2nd quarter of 2024 - Formycon AG
- Formycon reports audited annual results for the financial year 2023 – Looking back on a successful operative year and exceeded guidance - Formycon AG
- Formycon AG publishes preliminary figures for the 2023 financial year and guidance for the 2024 financial year - Formycon AG
- Formycon announces commercial launch of FYB201 (Ranibizumab) in Canada (RanoptoTM) and Switzerland (Ranivisio®) - Formycon AG
- Convincing overall performance – Formycon reports preliminary results for the financial year 2023 and exceeds forecast - Formycon AG
- Formycon and Fresenius Kabi reach settlement agreement for ustekinumab biosimilar candidate FYB202 in Europe and Canada - Formycon AG
- FYB201/Ranibizumab keeps gaining momentum with approvals and launches in the MENA region - Formycon AG
- Gedeon Richter becomes strategic investor of Formycon via equity investment - Formycon AG
- Formycon resolves on cash capital increase of EUR 82.84 million – all new shares were subscribed by Gedeon Richter as new strategic investor - Formycon AG
- Formycon Ranibizumab Biosimilar FYB201/CIMERLI® achieved a market share of 38% in the United States in December 2023 - Formycon AG
- View more press releases Close
Social media about Formycon
- Formycon on Wikipedia, Google News & Yahoo Finance
- Formycon on LinkedIn, Twitter & YouTube
Get in Touch
Contact by email its executives including Stefan Glombitza 
